The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 23, 2016
Filed:
Mar. 15, 2013
Applicant:
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Washington, DC (US);
Inventors:
Hee-Yong Kim, Potomac, MD (US);
Juan Jose Marugan, Gaithersburg, MD (US);
Erika E. Englund, Washington, DC (US);
Samarjit Patnaik, Gaithersburg, MD (US);
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 495/04 (2006.01); C07D 213/40 (2006.01); C07D 319/20 (2006.01); C07D 205/04 (2006.01); C07C 235/28 (2006.01); C07D 309/04 (2006.01); C07D 333/20 (2006.01); C07D 235/14 (2006.01); C07C 233/09 (2006.01); C07C 233/13 (2006.01); C07C 233/20 (2006.01); C07C 233/23 (2006.01); C07C 233/31 (2006.01); C07C 233/38 (2006.01); C07C 233/49 (2006.01); C07C 255/29 (2006.01); C07D 295/13 (2006.01); C07D 295/135 (2006.01); C07D 295/185 (2006.01); C07D 307/52 (2006.01);
U.S. Cl.
CPC ...
C07D 495/04 (2013.01); C07C 233/09 (2013.01); C07C 233/13 (2013.01); C07C 233/20 (2013.01); C07C 233/23 (2013.01); C07C 233/31 (2013.01); C07C 233/38 (2013.01); C07C 233/49 (2013.01); C07C 235/28 (2013.01); C07C 255/29 (2013.01); C07D 205/04 (2013.01); C07D 213/40 (2013.01); C07D 235/14 (2013.01); C07D 295/13 (2013.01); C07D 295/135 (2013.01); C07D 295/185 (2013.01); C07D 307/52 (2013.01); C07D 309/04 (2013.01); C07D 319/20 (2013.01); C07D 333/20 (2013.01); C07C 2101/04 (2013.01); C07C 2101/14 (2013.01);
Abstract
The invention provides derivatives of DEA which have increased potency and hydrolysis resistance as compared to DEA, and compositions thereof, as well as methods of using these derivatives to promote neurogenesis, neurite growth and/or length, and/or promote synaptogenesis.